| | | |
|
Friday, October 17, 2008
This booklet traces the first 50 years of the NPC's history in the context of major events in health care and medicine.
|
View
Download
|
|
Sunday, January 01, 2006
The Medicare Modernization Act of 2003 introduced new terminology that has now become commonplace among politicians, health policy analysts, and Medicare beneficiaries, including donut holes, PDPs, risk corridors, and low-income subsidies. This commentary by Avalere Health examines the confounding forces that influenced the development of this technically complex piece of legislation.
|
View
|
|
|
Saturday, April 01, 2000
A published meta-analysis of the incidence of adverse drug reactions (ADRs) in hospitalized patients concluded that ADRs rank as the fourth to sixth leading cause of death in the U.S. This conclusion generated considerable concern among health care providers, patients, and pharmaceutical manufacturers. To better understand the evidence behind this conclusion, a critical review of the source studies and the meta-analytic methods used to combine them was conducted. Findings suggest that the conclusions of the meta-analysis are invalid. (You must log in to Medscape in order to view this article. If you do not have a free log-in to Medscape, you can create one by clicking here.)
|
View
|
|
|
Saturday, March 01, 2003
Agitation and depression are the two most common behavioral complications of dementia. Although the behavioral symptoms have received less attention than the cognitive symptoms of dementia, they have serious consequences, including caregiver stress, premature institutionalization, and compromised quality of life for patients and their families. This study suggests that dementia complicated by mixed agitation and depression is among the most clinically challenging problems in long-term care, and that effective interventions and services are needed to address the complex treatment needs of this high-risk group.
|
View
|
|
Wednesday, October 17, 2001
Allergies are the sixth leading cause of chronic disease in the U.S., and cost the health care system over $18 billion annually. In this publication, a joint project between the Asthma and Allergy Foundation of America and NPC, we take a closer look factors influencing drug spending for allergies.
|
View
Download
Request a copy
|
|
|
Saturday, September 01, 2001
Critics of pharmaceutical spending point to the increase in the pharmaceutical “line item” in our overall health spending as cause for alarm. Lichtenberg's research examines the value of this spending in its complete context by exploring whether there are cost offsets associated with using newer and, most often, more expensive drugs. Lichtenberg finds that we are paying more, but we are getting a bigger “bang for our buck.” |
View
|
|
Tuesday, January 01, 2002
One in six Americans suffers from arthritis, and the CDC projects that number will grow to one in five by 2020. In this six-page brochure, a collaborative project between the Arthritis Foundation and NPC, we take a closer look at the factors influencing drug spending for treating arthritis.
|
View
Download
Request a copy
|
|
Thursday, October 17, 2002
The key finding in this report is that new drugs are yielding a wide range of benefits to our society that more than justify the investment needed to produce them. This report develops a comprehensive framework for assessing the value of pharmaceutical innovation that encompasses both the cost of bringing new products to market and the direct and indirect benefits. Fact sheet available.
|
View
Download
Request a copy
|
|
Wednesday, October 17, 2001
Asthma results in approximately 5,000 deaths annually in the U.S. and accounts for nearly half a million hospitalizations, 1.6 million emergency room visits, and over 10 million physician office visits. In this six-page brochure, a joint project between the Asthma and Allergy Foundation of America and NPC, we take a closer look at the factors influencing drug spending for the treatment of asthma.
|
View
Download
Request a copy
|
|
|
Friday, April 01, 2005
This work examines the extent to which the introduction of new drugs has increased society's ability to produce goods and services by increasing the number of hours worked per member of the working-age population. The study finds that the potential of medicines to increase employee productivity should be considered in the design of drug-reimbursement policies. Conversely, policies that broadly reduce the development and utilization of new drugs may ultimately reduce our ability to produce other goods and services.
|
View
|
